Drug Trial Radar · NCT07862114
A Study to Investigate the Effect of Omeprazole and Cyclosporine on Velzatinib in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Oct 16, 2026
Primary completion
Jan 12, 2027
Study completion Jan 12, 2027
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Oct 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will look at how two commonly used medicines, omeprazole and cyclosporine, influence the way the body absorbs, processes, and eliminates velzatinib in healthy volunteers.
Conditions
- Healthy Participants
- Gastrointestinal Neoplasms
Interventions
VelzatinibDrug
Velzatinib will be administered.
CyclosporineDrug
Cyclosporine will be administered.
OmeprazoleDrug
Omeprazole will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed plasma concentration (Cmax)Time frame: Up to 72 hours
- Area under the plasma concentration-time curve from time zero to 72 hours post-dose (AUC [0-72 hours])Time frame: Up to 72 hours
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.